Compare Resonance Speci. with Similar Stocks
Dashboard
The company is Net-Debt Free
Poor long term growth as Net Sales has grown by an annual rate of 7.50% and Operating profit at 2.71% over the last 5 years
The company has declared Positive results for the last 6 consecutive quarters
With ROE of 13.4, it has a Fair valuation with a 1.9 Price to Book Value
Majority shareholders : Promoters
Market Beating Performance
Stock DNA
Specialty Chemicals
INR 123 Cr (Micro Cap)
14.00
44
0.93%
-0.02
13.42%
1.87
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Jul-29-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Resonance Specialities Ltd is Rated Hold
Resonance Specialities Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Resonance Specialities Ltd: Valuation Shift Enhances Price Attractiveness Amid Specialty Chemicals Sector Dynamics
Resonance Specialities Ltd has witnessed a notable improvement in its valuation parameters, prompting a re-rating from Sell to Hold by MarketsMOJO. The specialty chemicals company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have shifted from very attractive to attractive, reflecting growing investor confidence amid robust financial metrics and outperforming returns relative to the Sensex.
Read full news article
Resonance Specialities Ltd is Rated Hold
Resonance Specialities Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 April 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 27 April 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article Announcements 
Board Meeting Intimation for Scheduled On 14/05/2026Inter Alia To Consider And Approve Audited Financial Results For The 4Th Quarter And Financial Year Ended March 31 2026 And To Recommend The Dividend For The Said Financial Year
30-Apr-2026 | Source : BSEResonance Specialties Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve audited financial results for the 4th quarter and financial year ended March 31 2026 and to recommend the dividend for the said financial year
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
06-Apr-2026 | Source : BSESubmission of certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2026.
Closure of Trading Window
16-Mar-2026 | Source : BSECLOSURE OF TRADING WINDOW
Corporate Actions 
14 May 2026
Resonance Specialities Ltd has declared 10% dividend, ex-date: 29 Jul 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (0.03%)
Makers Laboratories Limited (45.48%)
Sangeetha S (1.57%)
35.29%
Quarterly Results Snapshot (Standalone) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is 25.88% vs 18.90% in Dec 2024
YoY Growth in quarter ended Dec 2025 is 124.11% vs 16.67% in Dec 2024
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 21.03% vs 49.87% in Sep 2024
Growth in half year ended Sep 2025 is 37.66% vs 78.36% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 22.68% vs 37.67% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 65.24% vs 52.61% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 40.71% vs -5.97% in Mar 2024
YoY Growth in year ended Mar 2025 is 121.21% vs -40.60% in Mar 2024






